PATENT CLAIM ANALYSIS

Application Number: 15998702
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-02
Patent Classification: ["514", "183000"]

Abstract:
Administration of a hypoxia activated prodrug in combination with an antiangiogenic agent is useful for treating cancer.

Claim (Index 5):
The method of  claim 1 , wherein the antiangiogenic agent is selected from the group consisting of an anti-VEGF antibody, a VEGF-trap, an anti-VEGFR antibody, a VEGFR inhibitor, thalidomide, a D 114-Notch inhibitor, an anti-tubulin vascular disrupting agent (VDA), an angiopoietin-Tie2 inhibitor, a nitric oxide synthase (NOS) inhibitor, a cationic poly amino acid dendrimer, rapamycin, everolimus, temserolimus, a low molecular weight heparin, a SPARC (osteonectin) peptide, bevacizumab, ranibizumab, ramucirumab, atlibercept, interleukin 17 (IL-17), DC 101, sunitinib, sorafenib, pazopanib, AMG706, cediranib, vandetanib, vargatef, brivanib, XL-184, axitinib, tivozanib, thalidomide, lanalidomide, DMXAA, nadroparin, 2,5-dimethyl-celecoxib, cyclophosphamide, HBC, and tasquinimod.

Metadata:
- Claim Count in Document: 7.0
- Percentile: 96.0
- Lexical Diversity: 1.0
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14367168', '15480250', '13125303', '14043661', '13998269']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7862065021412664
- 35 USC 102 Novelty (BERT): 0.5143343973121092
- Combined Prediction Score: 0.7590192916583507
- Mean Citation Score: 260.037336
- Max Citation Score: 265.96304
- Similarity Product: 182.4386580597496

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test